TSC 203
Alternative Names: TSC-203; TSC-203-A0201Latest Information Update: 21 May 2024
At a glance
- Originator TScan Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer
- Preclinical Anal cancer; Cervical cancer
Most Recent Events
- 09 May 2024 TScan initiates enrolment in a phase I trial for Malignant Melanoma in the US
- 25 Apr 2024 Phase-I clinical trials in Head and neck cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Combination therapy) in USA (Parenteral) (TScan Therapeutics pipeline, April 2024) (NCT05973487)
- 25 Apr 2024 Phase-I clinical trials in Malignant melanoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Combination therapy) in USA (Parenteral) (TScan Therapeutics pipeline, April 2024) (NCT05973487)